

Note: This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.

August 14, 2026

To All Concerned Parties,

Company: Asahi Intecc Co., Ltd.
Representative: Kenji Miyata, President & CEO
(Securities code: 7747, Prime of Tokyo Stock Exchange and Premier of
Nagoya Stock Exchange)
Contact:
Mizuho Ito, Member of Board & CFO, General Manager of Administration
(TEL. +81-561-48-5551)

Regarding the Execution of an Exclusive Distribution Agreement in the Japanese Market for an Intracranial Occlusion Device

1. Overview of the Agreement

Asahi Intecc (the “Company”) announces that its Board of Directors resolved today to enter into an exclusive distribution agreement with Nuvascular, Inc. (“Nuvascular”), a U.S. company, for the exclusive distribution in Japan of Nuvascular’s intracranial occlusion device, “HARBOR”.

The subject product, “HARBOR,” is a medical device currently under development, with clinical trials underway for the treatment of cerebral aneurysms. It has not yet obtained regulatory approval in Japan.

Based on this agreement, the Company plans to proceed with preparations to obtain regulatory approval in Japan. Following approval, the Company plans to commence direct sales to medical institutions in Japan through its wholly-owned consolidated subsidiary, Asahi Intecc J-sales, Inc.

The term of the exclusive distribution rights in Japan under this agreement is five years from the date of regulatory approval. Following this initial term, the agreement is expected to be renewed based on mutual agreement between the two companies.

“HARBOR” is a medical device designed to be placed inside a cerebral aneurysm as a mesh-like structure. By restricting blood flow into the aneurysm, the device is intended to promote thrombus formation within the aneurysm and subsequent aneurysm occlusion. The market for this treatment is expected to expand in the future.

The Asahi Intecc Group has developed products such as guidewires, guiding catheters, and balloon guiding catheters in the field of neuroendovascular treatment, while building relationships with medical institutions and healthcare professionals. As “HARBOR” is used in the same treatment area as these existing products, synergies are expected with the Group’s sales network, customer base, and product portfolio.

The Company expects this product to become a new treatment option for cerebral aneurysms in Japan and to provide new value to patients and the medical community.

2. About Nuvascular, Inc.

Nuvascular, Inc. is a medical device company headquartered in California, U.S. The company develops and manufactures innovative therapeutic solutions, including the “HARBOR Occlusion Device,” a self-expanding braided nitinol implant, by leveraging its proprietary braiding and processing technologies.

Note: This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.

Company name	Nuvascular, Inc.
Location	California, U.S.
Name and title of representative	Matthew Joseph Fitz, Chief Executive Officer
Establishment	March 2023
Business area	Research, development, manufacturing, and sales of medical devices for endovascular embolization procedures

3. Date

Date of Board Resolution: August 14, 2026

Date of Agreement Execution: August 14, 2026

4. Future Outlook

This matter will have no impact on the Group's consolidated financial results for the current fiscal year.

This news release is intended to provide members of the media, shareholders, investors, and other stakeholders with fair and timely information regarding the Company's corporate activities and initiatives. This news release may contain information regarding medical devices, pharmaceuticals, products, or services handled by the Company, including information on products that have not been approved in Japan. Such information is not intended as advertising, solicitation of customers, or medical advice.